share_log

Oppenheimer Maintains Outperform on Tandem Diabetes Care, Raises Price Target to $58

Oppenheimer Maintains Outperform on Tandem Diabetes Care, Raises Price Target to $58

Oppenheimer認爲Tandem Diabetes Care表現良好,將價格目標調高至58美元
Benzinga ·  06/10 07:22

Oppenheimer analyst Steven Lichtman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and raises the price target from $47 to $58.

Oppenheimer分析師Steven Lichtman維持Tandem Diabetes Care(納斯達克股票代號:TNDM)的跑贏大盤評級,並將目標股價從47美元上調至58美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論